

Adrenal Disorders for the USMLE Step One...

...the Adrenal Medulla:

Pheochromocytoma (Pheo) and MEN2 Syndrome


Howard J. Sachs, MD
www.12DaysinMarch.com

Adrenal Medulla: Background

- Key facts to know about the Medulla
 - Derived from neural crest
 - Function as modified autonomic ganglion
 - Stimulated by SNS (**Acetylcholine**) to release catecholamines
 - Principle product: **Epinephrine**

Adrenal Medulla: Background


- Key facts to know about the Medulla
 - Derived from neural crest
 - Function as modified autonomic ganglion
 - Stimulated by SNS (**Acetylcholine**) to release catecholamines
 - Principle product: Epinephrine



In the diagram above, choose the appropriate stimulus to hormone release at the region designated by letter E.

Adrenal Medulla: Background


- Key facts to know about the Medulla
 - Derived from neural crest
 - Function as modified autonomic ganglion
 - Stimulated by SNS (**Acetylcholine**) to release catecholamines
 - Principle product: Epinephrine



In the diagram above, choose the appropriate stimulus to hormone release at the region designated by letter E.


Adrenal Medulla: Background

- Key facts to know about the Medulla
 - Derived from neural crest
 - Function as modified autonomic ganglion
 - Stimulated by SNS (Acetylcholine) to release catecholamines
 - Principle product: **Epinephrine**




Adrenal Medulla: Background

- Key facts to know about the Medulla
 - Derived from neural crest
 - Function as modified autonomic ganglion
 - Stimulated by SNS (Acetylcholine) to release catecholamines
 - Principle product: **Epinephrine**




Tyrosine hydroxylase is rate-limiting

Adrenal Medulla: Metabolism



MAO: monoamine oxidase
COMT: catechol-O-methyltransferase

Adrenal Medulla: Metabolism



Implications:

1. In assessing medullary hyperfunction, biochemical metabolites are the diagnostic test of choice (metanephrines and VMA)
2. MAO inhibitor results in increased levels of catecholamines

Pheochromocytoma/MEN 2

- Background
 - Catecholamine-secreting tumor of the adrenal medulla
 - Only 10% malignant
 - Majority are sporadic but the **familial syndromes capture the imagination of the NBME**
 - AD: MEN 2, VHL (Von Hippel-Lindau), Neurofibromatosis (NF-1)
- Pathology
- Clinical
- Data
- Treatment

Pheochromocytoma/MEN 2

- Background
- Pathology
 - Composed of chromaffin (neuroendocrine) cells
 - EM: neurosecretory granules
 - Tumors are generally small circumscribed lesions but can get pretty enormous
 - No histologic features that predict malignant behavior.
 - They are malignant if they metastasize
- Clinical
- Data
- Treatment

Pheochromocytoma/MEN 2


- Background
- Pathology
 - Composed of chromaffin (neuroendocrine) cells
 - EM: neurosecretory granules
 - Tumors are generally small circumscribed lesions but can get pretty enormous
 - No histologic features that predict malignant behavior.
 - They are malignant if they metastasize
- Clinical
- Data
- Treatment

Pheochromocytoma/MEN 2

- Background
- Pathology
- Clinical
 - Classic: (paroxysmal) HTN plus HA, Sweats, Palpitations
 - Reality: incidental (imaging), screening familial syndrome
 - Tend to be **bilateral** if familial

Pheochromocytoma/MEN 2

- Data
 - Plasma metanephrines; Urine catecholamines (fractionated)
 - Imaging: CT/MRI, Nuclear: (MIBG/PET)



Pheochromocytoma/MEN 2

- Background
- Pathology
- Clinical
- Data
- Treatment
 - Adrenalectomy
 - Medical pretreatment with α -1-antagonist (**phenoxybenzamine**) →
 β -blocker (HR control)
- Special Notes


Pheochromocytoma/MEN 2

- Background
- Pathology
- Clinical
- Data
- Treatment
- Special Notes
 - Complication: Catecholamine-induced CM
 - Takotsubo-like syndrome
 - Extra-adrenal: 10% (referred to as paraganglionomas)
 - 95% within abdomen (para-aortic location)
 - VHL: loss of function of a tumor suppressor gene
 - VHL - ubiquitin ligase induces degradation of HIF
 - Components include **Pheo**, **Renal cell**, Hemangioblastoma



Ca²⁺

MEN 1




MEN 1
Pituitary
Parathyroid
Pancreas (neuroendocrine)

Pheochromocytoma
MEN 2 Syndromes

Ca²⁺

RET



MTC

Pheo

MTC

Pheo

MEN 2a

RET

MEN 2b

MTC

Pheo


PTH

Gain of function

Marfanoid

The most challenging part of the MEN syndromes is knowing you are in the middle of one.

If a question seems convoluted with disparate features, think MEN



The most challenging part of the MEN syndromes is knowing you are in the middle of one.



If a question seems convoluted with disparate features, think MEN

Reality Check:

100% - MTC

50% - Pheo

Pheochromocytoma MEN 2 Syndromes



The most challenging part of the MEN syndromes is knowing you are in the middle of one.

If a question seems convoluted with disparate features, think MEN

Reality Check:

100% - MTC
50% - Pheo


2a

20% - PTH hyperplasia

PTH:
Hypercalcemia
Stones

Pheo:
HTN, palpitation,
HA, sweats

Pheochromocytoma MEN 2 Syndromes



The most challenging part of the MEN syndromes is knowing you are in the middle of one.

If a question seems convoluted with disparate features, think MEN

Reality Check:

100% - MTC


50% - Pheo

2b

Marfanoid Features

Mucosal Neuromas

Pheochromocytoma MEN 2 Syndromes



RET

MTC

Pheo

RET

MEN 2b

MTC

Pheo

Gain of
function

Marfanoid

Reality Check:

100% - MTC

50% - Pheo

2b


Marfanoid Features

MSK

(no aorta, lens)

Mucosal Neuromas


Tongue, Lips



Flesh colored nodules
Neuromas
(not lipomas or angiofibromas)

Pheochromocytoma
MEN 2 Syndromes

RET



MTC

Pheo

RET

MEN 2b

MTC
Pheo

Gain of
function

Marfanoid

MEN 2/ Medullary Thyroid Carcinoma

- **Background**
 - AD genetic syndromes with high penetrance and **RET** mutations characterized by **Medullary Thyroid Carcinoma** (100%), Pheochromocytoma (50%) plus:
 - 2A: Parathyroid hyperplasia (20%).
 - 2B: Mucocutaneous (neuromas) and MSK (Marfan-like MSK features; aorta/lens not involved).
 - **Aggressive tumor with majority having metastases at time of dx.**
- Pathogenesis/Pathology
- Clinical
- Data/Diagnostics
- Treatment

MEN 2/ Medullary Thyroid Carcinoma

- Pathogenesis
 - RET gene: codes for a protein that is a receptor tyrosine kinase. It induces growth and differentiation signals .
 - Gain of function mutation with constitutively active.
- Pathology

MEN 2/ Medullary Thyroid Carcinoma

- Pathogenesis

- RET gene: codes for a protein that is a receptor tyrosine kinase. It induces growth and differentiation signals .
- Gain of function mutation with constitutively active

- Pathology

- Precursor
- Carcinoma
- amyloid de



tracellular



Calcitonin



ango red stain with
apple-green
birefringence under
polarized light

MEN 2/ Medullary Thyroid Carcinoma

- Pathogenesis

- RET gene: codes for a protein that is a receptor tyrosine kinase. It induces growth and differentiation signals .
- Gain of function mutation with constitutively active.

- Pathology

- Precursor: early finding of parafollicular (C-cell) hyperplasia
- Carcinoma: uniform cells that stain (+) for calcitonin with **extracellular amyloid deposits that stain (+) for Congo red.**

MEN 2/ Medullary Thyroid Carcinoma

- Pathogenesis


- RET gene: codes for a protein that is a receptor tyrosine kinase. It induces growth and differentiation signals .
- Gain of function mutation with constitutively active.

- Pathology

- Precursor: early finding of parafollicular (C-cell) hyperplasia
- Carcinoma: uniform cells that stain (+) for calcitonin with **extracellular amyloid deposits that stain (+) for Congo red.**



Calcitonin



Congo red stain with
apple-green
birefringence under
polarized light

MEN 2/ Medullary Thyroid Carcinoma

- **Clinical:** initial presentation in MEN 2 Syndromes
 - Solitary nodule +/- cervical adenopathy
 - 2A: HyperPTH/Pheo symptoms
 - 2B: Mucocutaneous neuromas (lips/tongue)/Pheo symptoms



MEN 2/ Medullary Thyroid Carcinoma

- Background
- Pathogenesis/Pathology
- Clinical
- **Data/Diagnostics**
 - FNA with immunohistochemical stain for calcitonin
 - Serum **Calcitonin**: serial assessment (known cancer) or screening (in familial syndromes)
 - IV **pentagastrin** or calcium stimulation
 - Level correlates with size of mass
 - May express **CEA** - monitoring, not diagnostic
- Treatment

MEN 2/ Medullary Thyroid Carcinoma

- Background
- Pathogenesis/Pathology
- Clinical
- Data/Diagnostics
- **Treatment**
 - Thyroidectomy - MTC is an aggressive tumor; **found early** (or in setting of familial syndrome), excision is definitive rx.
 - Most have metastasized at time of dx.

MEN 2

Pheochromocytoma & Medullary Thyroid Carcinoma

- Patient with HTN/palpitations, blah, blah → MTC derivative
 - RET mutation
 - Calcitonin
 - Amyloid deposits: Congo Red stain
 - Treatment → Thyroidectomy

MEN 2

Pheochromocytoma & Medullary Thyroid Carcinoma

- Patient with HTN/palpitations, blah, blah → MTC derivative
 - RET mutation
 - Calcitonin
 - Amyloid deposits: Congo Red stain
 - Treatment → Thyroidectomy
- Patient with neck mass stains (+) with Congo Red (or calcitonin), what other signs/symptoms might they have? → Pheo derivative
 - Symptoms (HTN, palpitations, HA, sweats)
 - Metabolites: VMA/Metanephrines
 - Unilateral v Bilateral tumor of the medulla

MEN 2

Pheochromocytoma & Medullary Thyroid Carcinoma

- Patient with HTN/palpitations, blah, blah → MTC derivative
 - RET mutation
 - Calcitonin
 - Amyloid deposits: Congo Red stain
 - Treatment → Thyroidectomy
- Patient with neck mass stains (+) with Congo Red (or calcitonin), what other signs/symptoms might they have? → Pheo derivative
 - Symptoms (HTN, palpitations, HA, sweats)
 - Metabolites: VMA/Metanephrines
 - Unilateral v Bilateral tumor of the medulla
- Distinguish:
 - 2a (HyperPTH) from 2b (Marfanoid/Neuromas)
 - MEN 1 (Pituitary, Parathyroid, Pancreas) v MEN 2
 - MEN 2 from VHL (Renal Cell, loss of suppressor)

Adrenal Disorders for the USMLE Step One:

the Adrenal Medulla and...

Pheochromocytoma and MEN2 Syndrome

Howard J. Sachs, MD

Email: Howard@12DaysinMarch.com